Skip to content
Screener

Intellia Therapeutics NTLA Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$7.7MMiss by $5.3M
EPS-$0.80Miss by $0.00
Revenue estimate$13.0M
EPS estimate-$0.80
“These data serve as strong validation for in vivo gene editing and lonvo-z's potential to transform the treatment paradigm for patients who are burdened by this disease.”
John Leonard

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$9.7M
EPS estimate-$0.82

Financials

Q2 2026

Income statement

See full
Revenue$7.7M-46.2%
Operating income-$112.8M-2.5%
Net income-$106.6M-5.3%
EPS (diluted)-$0.80+18.4%

Balance sheet

See full
Cash & equivalents$106.1M-32.0%
Total debt$73.4M-28.4%
Total equity$727.7M+202%
Total assets$857.2M-4.6%

Cash flow

See full
Operating cash flow-$83.1M+16.6%
CapEx$1.8M+657%
Free cash flow-$84.9M+15.0%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.61B+20.9%
Enterprise value$1.58B+23.4%
P/S27.1×+1.9×

Profitability

See full
Operating margin-711.7%-149pp
Net margin-672.2%-139pp
FCF margin-586%-123pp

Returns & leverage

See full
Debt / equity0.1×—
Current ratio6.6×+1.5×

FAQ

When did Intellia Therapeutics report Q2 2026 earnings?
Intellia Therapeutics (NTLA) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Intellia Therapeutics's Q2 2026 revenue and EPS?
Intellia Therapeutics reported revenue of $7.7M and eps of $-0.80 for Q2 2026.
Did Intellia Therapeutics beat estimates in Q2 2026?
Revenue missed the consensus estimate of $13.0M by $5.3M. EPS missed the consensus estimate of $-0.80 by $0.00.
How did Intellia Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 46.2% from $14.2M a year earlier and eps grew 19.2% from $-0.99.
Where can I find Intellia Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-336772) and the 10-Q periodic report (0001193125-26-337952) directly on SEC EDGAR. The filing index links above go to sec.gov.